Randomized controlled trial protocol of ASSIP and ACT for suicide prevention among Iranian suicide attempters

ASSIP 和 ACT 在伊朗自杀未遂者中预防自杀的随机对照试验方案

阅读:1

Abstract

BACKGROUND: Suicide attempts are a major global health concern, and more effective interventions are needed. This study aims to compare the effectiveness of the Attempted Suicide Short Intervention Program (ASSIP) and Acceptance and Commitment Therapy (ACT) in reducing suicidal ideation and mental pain among suicide attempters. METHODS: This randomized controlled trial (RCT) will recruit 60 participants (20 in each group) who have attempted suicide and whose contact information has been obtained from the Mental Health Unit of Eslamshahr Health Network. Participants will be randomly assigned to three groups: one receiving ASSIP in addition to treatment as usual (TAU), one receiving ACT alongside TAU, and a control group receiving TAU only. Data will be collected using the Beck Scale for Suicide Ideation (BSSI) and the Orbach & Mikulincer Mental Pain Scale (OMMP) at pre-test, post-test, and follow-up stages. Primary outcomes are suicidal ideation and mental pain. Data on self-harm behaviors and re-attempts will also be descriptively collected during follow-up. RESULTS: We hypothesize that both ASSIP and ACT will lead to greater improvements in suicidal ideation and mental pain compared to the control group. We will also compare the effectiveness of the two interventions. CONCLUSIONS: This study will provide valuable insights into the comparative effectiveness of ASSIP and ACT interventions for suicide attempters. The results are expected to inform clinical practice and contribute to evidence-based suicide prevention strategies. Findings will be disseminated through scientific publications, regardless of whether outcomes are positive, negative, or neutral. TRIAL REGISTRATION: The trial was registered at ClinicalTrial.gov NCT07132099 on 20 August 2025. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s44192-026-00406-7.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。